Oct 24th 2012 - Edison Investment Research today published a report on update entitled "One Step To Commercial". In summary, the report says:
The FDA Gastrointestinal Drugs Advisory Committee’s recent unanimous vote (12 yes, 0 no, 0 abstain) in favour of NPS's Gattex (teduglutide) for adult short bowel syndrome (SBS) puts this product on track for launch in early 2013. New data from the ongoing STEPS 2 study also show that 14% of patients achieved complete independence from parenteral nutrition (PN) and/or IV fluids on Gattex, the goal of therapy. However, NPS’s current valuation prices in an expectation of approval on or before the PDUFA date of 30 December 2012.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
